GLYCのニュース
GlycoMimetics Has Few Risks, Great Outlook In Leukemia (NASDAQ:GLYC) 2023/04/04 12:35:08 Seeking Alpha
GlycoMimetics'' lead drug candidate is in Phase 3 development for multiple leukemia indications. See why we recommend a buy on GLYC.
GlycoMimetics, Inc. (GLYC) Q4 2022 Earnings Call Transcript 2023/03/29 15:09:04 Seeking Alpha
GlycoMimetics, Inc. (NASDAQ:NASDAQ:GLYC) Q4 2022 Results Conference Call March 29, 2023 8:30 AM ETCompany ParticipantsChristian Dinneen-Long - General Counsel and Company SecretaryHarout…
GlycoMimetics: Q4 Earnings Snapshot 2023/03/29 11:06:28 WTOP
ROCKVILLE, Md. (AP) — ROCKVILLE, Md. (AP) — GlycoMimetics Inc. (GLYC) on Wednesday reported a loss of $10.2 million in…
GlycoMimetics GAAP EPS of -$0.19 misses by $0.02 2023/03/29 11:04:13 Seeking Alpha
GlycoMimetics press release (GLYC): Q4 GAAP EPS of -$0.19 misses by $0.02.Cash and cash equivalents as of December 31, 2022 were $47.9 million.Cash and cash equivalents expected to…
GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Year-end 2022 2023/03/29 11:00:00 Business Wire
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today reported its financial results and highlights for the quarter and year ended December 31, 2022. Cash and cash equivalents as of December 31, 2022 were $47.9 million. After year-end, the company raised an additional $28.7 million in net proceeds from its “at-the-market” (ATM) sales faci
Do you want to know where to find good stock? Take a look at GlycoMimetics Inc.’s (NASDAQ:GLYC) Sentiment Analysis 2023/01/30 20:08:00 US Post News
Currently, GlycoMimetics Inc.’s (GLYC) stock is trading at $3.03, marking a fall of -10.62% from last night’s close. At this price, the stock is -15.83% below its 52-week high of $3.60 and 494.12% above its 52-week low of $0.51. Based on the past 30-day period, the stock price is -15.28% below the high and +26.03% […]
Surprising stocks: Meiwu Technology Company Limited (NASDAQ:WNW 6.67%), GlycoMimetics, Inc. (NASDAQ:GLYC -2.21%) 2023/01/26 13:55:07 Stock Equity
WNW has seen its SMA50 which is now -71.32%. In looking the SMA 200 we see that the stock has seen a -67.17%. GLYC has seen its SMA50 which is … The post Surprising stocks: Meiwu Technology Company Limited (NASDAQ:WNW 6.67%), GlycoMimetics, Inc. (NASDAQ:GLYC -2.21%) appeared first on Stocks Equity .
GlycoMimetics Inc. (GLYC) deserves closer scrutiny 2023/01/11 16:00:00 US Post News
A share of GlycoMimetics Inc. (NASDAQ:GLYC) closed at $2.90 per share on Tuesday, up from $2.78 day before. While GlycoMimetics Inc. has overperformed by 4.32%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, GLYC rose by 108.63%, with highs and lows ranging from $3.30 to $0.51, […]
GlycoMimetics: A Cancer-Cure Lottery Ticket Grabbing My Attention (NASDAQ:GLYC) 2023/01/03 12:40:57 Seeking Alpha
GlycoMimetics may have discovered a successful treatment for AML leukemia, currently with a 5-year survival rate of around 30%. Find out why GLYC is a Buy.
GlycoMimetics Inc. (NASDAQ: GLYC) Stock Forecast: $13.00 Per Share In 2022 With Positive Signs 2022/12/28 21:00:00 Marketing Sentinel
In today’s recent session, 0.85 million shares of the GlycoMimetics Inc. (NASDAQ:GLYC) have been traded, and its beta is 2.32. Most recently the company’s share price was $2.38, and it changed around $0.14 or 6.23% from the last close, which brings the market valuation of the company to $116.93M. GLYC at last check was trading … GlycoMimetics Inc. (NASDAQ: GLYC) Stock Forecast: $13.00 Per Share In 2022 With Positive Signs Read More »
Investing in GlycoMimetics Inc. (GLYC) might be a great opportunity, but the stock is a bit overvalued 2022/11/29 14:00:00 US Post News
As of Monday, GlycoMimetics Inc.’s (NASDAQ:GLYC) stock closed at $2.15, up from $2.05 the previous day. While GlycoMimetics Inc. has overperformed by 4.88%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, GLYC rose by 20.11%, with highs and lows ranging from $2.43 to $0.51, whereas the […]
GlycoMimetics Inc. (NASDAQ:GLYC) Is -1.44% Lower Than A Week Ago, Can It Hit Well Above -$0.03? 2022/11/26 13:00:00 Marketing Sentinel
In last trading session, GlycoMimetics Inc. (NASDAQ:GLYC) saw 0.27 million shares changing hands with its beta currently measuring 1.97. Company’s recent per share price level of $2.05 trading at -$0.04 or -1.91% at ring of the bell on the day assigns it a market valuation of $99.30M. That closing price of GLYC’s stock is at … GlycoMimetics Inc. (NASDAQ:GLYC) Is -1.44% Lower Than A Week Ago, Can It Hit Well Above -$0.03? Read More »
How did GlycoMimetics Inc. (GLYC) fare last session? 2022/11/21 14:40:00 US Post News
GlycoMimetics Inc. (NASDAQ:GLYC) closed Friday at $2.25 per share, up from $2.08 a day earlier. While GlycoMimetics Inc. has overperformed by 8.17%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, GLYC rose by 22.28%, with highs and lows ranging from $2.12 to $0.51, whereas the simple […]
BRY, CRCT and IMRX are among after hour movers 2022/11/16 23:06:24 Seeking Alpha
Gainers: GlycoMimetics (GLYC) +9%. EDAP TMS (EDAP) +6%
Why Tattooed Chef Shares Dipped Around 15%; Here Are 95 Biggest Movers From Friday 2022/11/14 07:35:17 Benzinga
Gainers ShiftPixy, Inc. (NASDAQ: PIXY ) shares surged 56.6% to settle at $19.10 on Friday. Shares of several companies in the broader industrial space traded higher on continued hopes of softer Fed policy after CPI this week showed October inflation below estimates. Exela Technologies, Inc. (NASDAQ: XELA ) gained 50.3% to close at $0.2780. The company is expected to report Q3 results on November 14, 2022. uCloudlink Group Inc. (NASDAQ: UCL ) jumped 49.6% to close at $1.90. uCloudlink Group is expected to report Q3 financial results on November 16, 2022. Core Scientific, Inc. (NASDAQ: CORZ ) gained 44.3% to settle at $0.1981. Compass, Inc. (NYSE: COMP ) jumped 44% to close at $3.50. Compass posted a wider-than-expected loss for its third quarter, while sales topped estimates. Kaleyra, Inc. (NYSE: KLR ) climbed 38.5% to close at $0.90. Kaleyra extended Oracle partnership to leverage Oracle Cloud. Nutex Health Inc. (NASDAQ: NUTX ) gained 37.7% to close at $1.16. MiNK Therapeutics, Inc. (NASDAQ: INKT ) jumped 35.8% to close at $3.00.